The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 361:308-310 July 16, 2009 Number 3
NextNext

Inhibitors of Factor VIII in Hemophilia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Supplementary Material
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Viel, K. R.
-PubMed Citation
To the Editor: Viel et al. (April 16 issue)1 propose that treatment of hemophilia A with factor VIII that is matched for polymorphic variants may reduce the risk of the development of factor VIII inhibitors. Their study included patients with different types of causative mutations and disease severity. We believe that stratification of patients according to the presence or absence of factor VIII protein, whether it is functional or not, may be more suitable than evaluation of mismatched factor VIII as a risk factor for the development of inhibitors.

Mismatched replacement therapy appears to be a risk factor in patients . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.